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Abstract
Background: The oldest old is the fastest growing age group worldwide and the most prone to severe disability,
especially in relation to loss of cognitive function. Improving our understanding of the predictors of cognitive,
physical and psychosocial wellbeing among the oldest old can result in substantial benefits for the individuals and
for the society as a whole.
The Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study investigated risk factors and determinants of
cognitive impairment in a population-based longitudinal cohort, which was first examined between 1972 and 1992,
when individuals were in their midlife, and re-assessed in 1998 and 2005–2009. Most of the study participants are
currently aged 85 years or older. We aim to re-examine the cohort’s survivors and gain further insights on the
mechanisms underlying both cognitive and overall healthy ageing at old age.
Methods: CAIDE85+ is the third follow-up of the CAIDE study participants. All individuals still alive and living in the
Kuopio and Joensuu areas of Eastern Finland, from the original CAIDE cohort (two random samples, N = 2000 + ~ 900),
will be invited to a re-examination. The assessment includes self-reported data related to basic demographics and
lifestyle, as well as psychosocial and physical health status. Cognitive and physical evaluations are also conducted.
Blood biomarkers relevant for dementia and ageing are assessed.
Primary outcomes are the measurements related to cognition and daily life functioning (CERAD, Trail Making Test-A,
Letter-Digit Substitution Test, Clinical Dementia Rating and Activities of Daily Living). Secondary endpoints of the study
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are outcomes related to physical health status, psychosocial wellbeing, as well as age-related health indicators.
Discussion: Through a follow-up of more than 40 years, CAIDE85+ will provide invaluable information on the risk and
protective factors that contribute to cognitive and physical health, as well as ageing and longevity.
Study registration: The present study protocol has been registered at https://clinicaltrials.gov/ (registration nr NCT0393872
7, date 03.05.2019).
Keywords: Ageing, CAIDE, Cognitive decline, Dementia, Disability, Longevity, Longitudinal cohort study, Midlife risk factors,
Physical functioning, Protocol
Background
The rapid growth of the oldest section of the population is
setting new challenges for modern societies worldwide.
The oldest old, often defined as people aged 85 years or
more [1], is currently the fastest-growing age group in the
developed countries, as well as the most prone to disabling
conditions and use of long-term care services [2]. Demen-
tia, the main reason for institutionalisation among the old-
est old [3], and Alzheimer’s disease (AD), its most
common cause, are currently one of the world’s key global
public health priorities, as well as a major social and eco-
nomic burden [4]. Approximately 25–30% of people in
their early 90s, 50% of those in their late 90s, and 60% of
those aged 100 years or more live with AD or other forms
of dementia [5]. Reducing the risk of developing dementia
and improving the overall health status, psychosocial well-
being, and the quality of life of the oldest old would have
important individual and public health, as well as societal
and economic benefits.
Several midlife modifiable cardiovascular risk factors, in-
cluding hypertension, hypercholesterolemia, diabetes mel-
litus, obesity, smoking, physical inactivity, and unhealthy
diet, have been linked to dementia at older ages [4, 6, 7],
creating opportunities for prevention [8, 9]. Furthermore,
a strong association of poor physical health status with de-
mentia has been found among the oldest old [10]. Poten-
tial predictors of longevity, such as healthy lifestyle at
midlife [11], higher socioeconomic status [12], and psy-
chosocial support [13] have also been proposed. However,
prospective studies with repeated assessments extending
to the oldest old are still relatively rare.
Rationale
The Cardiovascular Risk Factors, Aging and Dementia
(CAIDE) study is a population-based cohort study initi-
ated in 1998 to investigate the potential role of midlife
modifiable risk and protective factors in the development
of dementia [14, 15]. The re-examinations carried out so
far have provided essential knowledge on the role of vas-
cular and lifestyle risk factors [15–20], including interac-
tions with genetics [14]. Using the study data, the CAIDE
Dementia Risk Score was the first tool developed to pre-
dict the risk of late-life dementia based on lifestyle and
cardiovascular risk factors at midlife. It is currently used
as a research tool [21–23], and it enabled the selection of
individuals at increased risk of cognitive decline in the first
successful larger-scale and longer-term multidomain life-
style trial in the dementia prevention field [24].
Aims
Ten years after the second follow-up, most of the
CAIDE participants belong now to the oldest old age
group. The new CAIDE85+ study, which is the third
follow-up within this cohort, aims to further investigate
risk and protective factors for dementia, as well as im-
prove our understanding of the life-course factors affect-
ing the ageing process. To this aim, the cognitive and
physical health status, daily life functioning, as well as
lifestyle, psychosocial wellbeing, and quality of life, are
investigated in this cohort.
Methods
Overall design of the CAIDE study
CAIDE is a prospective longitudinal cohort study started
in 1998 in Eastern Finland; CAIDE85+ is its third re-
examination. CAIDE and CAIDE85+ have been ap-
proved by the Ethics Committee, Hospital District of
Northern Savo (Finland), and the CAIDE85+ study
protocol has been registered at https://clinicaltrials.gov/
(registration nr NCT03938727, date 03.05.2019).
In 1998, a first random sample of potential partici-
pants was identified from Finnish population-based
cross-sectional surveys (North Karelia project in 1972
and 1977, FINMONICA study in 1982 and 1987, Fig. 1)
[25–28]. A total of 2000 individuals living in the Kuopio
and Joensuu areas of Eastern Finland and assessed at
midlife (average age = 50.4 ± 6 years) were invited to the
first re-examination of the CAIDE study (Fig. 1), and
1449 agreed to participate. The second re-examination
took place between 2005 and 2008. A total of 1426 of
the original 2000 participants were still alive and living
in the Kuopio and Joensuu areas, and a total of 909
agreed to participate (Fig. 1).
In 2006, a second random sample of 897 people was
identified from the 1987 FINMONICA and 1992 FIN-
RISK study cohorts. A total of 445 individuals were
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eligible (still alive, living in Kuopio and not already in-
vited to CAIDE), and 268 were re-examined between
2006 and 2009 (Fig. 1).
The CAIDE85+ study presented here includes both
CAIDE random samples; recruitment and re-
examinations started in June 2019 and will continue
until 2021, more than 40 years after the baseline (mid-
life) assessments.
Population, recruitment, and inclusion/exclusion criteria
Every individual who was part of a CAIDE random sam-
ple and is still alive and living in the Kuopio or Joensuu
areas at the time of recruitment is considered eligible for
participation. No other inclusion or exclusion criteria
are applied.
Eligible participants are identified through the national
population registry and invited by post. From the first
CAIDE sample, 425 eligible individuals were identified
in May 2019; from the second CAIDE sample, 381 eli-
gible individuals were identified in September 2019.
Based on previous recruitment rate, and considering the
frailty level as well as the high rate of comorbidities in
this age group, 500 participants are estimated to be en-
rolled in the present follow-up.
Participants are asked to nominate a study informant,
i.e. a relative or a friend who is at least 18 years old and
who may or may not live with the participant, to provide
information related to physical and cognitive health of
the participant. The recruitment of a study informant is
encouraged and supported but is not a binding require-
ment to be included in the study.
Data collection
The data collection is conducted through questionnaires,
interview, and physical and cognitive examinations by a
research nurse trained for the study procedures. Based
on the participant’s preferences, the visit may take place
either at the research site or at the participant’s
domicile.
At the baseline (midlife) visit, data were collected re-
garding socio-demographics (age, sex, education, marital
status, occupation, income), vascular risk factors (e.g.
blood pressure, blood lipids, body mass index), lifestyle
(e.g. smoking, alcohol, physical activity, diet), psycho-
social factors, and physical health status. At the CAIDE
re-examinations, a detailed cognitive evaluation was con-
ducted, including a 3-step protocol for the diagnosis of
dementia [29], and apolipoprotein E genotype was
Fig. 1 CAIDE study diagram. a: participants from this cohort were included in the first random sample identified in 1998; b: participants from this
cohort were included in the second random sample identified in 2006; c: includes participants from the 1972, 1977, 1982, and 1987 midlife
cohorts; d: includes participants from the 1987 and 1992 midlife cohorts
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assessed. In the present CAIDE85+ re-examination, data
collection has been harmonised with previous follow-
ups, with some adaptations and additions specifically
relevant for the 85+ population (e.g. addition of the
frailty index and indicators of malnutrition), or recent
scientific developments related to the aims of the study
(e.g. additional assessment of the quality of sleep and
oral health). In Table 1, a full summary and comparison
of the assessments carried out at each examination is
presented.
Primary outcomes
The primary outcomes of CAIDE85+ are cognitive per-
formance, daily life functioning, dementia and mild cog-
nitive impairment (MCI).
Cognitive performance is evaluated using the Finnish
version of the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) test battery, which was
carried out also during the 2005–2008 re-examination
[30]. This includes: Modified 15-item Boston Naming
Test [54], Category fluency [33], Mini-Mental State
Examination [31], 10-Word Recall Task (10 word learn-
ing, recall and recognition) [30], Constructional Praxis
[55] and Recall [56], and Clock Drawing Test [57]. In
addition to CERAD, the Trail Making Test part A [35]
and the Letter-Digit Substitution Test [37] are also used.
Daily life functioning. Functioning level is measured
through the Clinical Dementia Rating (CDR) [41, 42],
for which a semi-structured interview with the partici-
pant and the study informant will be conducted. Activ-
ities of Daily Living (ADL) is assessed using both the
Katz Index of Independence in Activities of Daily Living
and the Lawton-Brody Scale of Instrumental Activities
of Daily Living [38–40].
Dementia diagnoses (including the type of dementia) is
ascertained from medical records and data linkage to na-
tional registers, such as hospital discharge, outpatient,
drug reimbursement, and causes of death registers. MCI
is defined based on standard criteria [58] which include:
abnormal cognitive test performance; subjective memory
complaint; and minimal or no impairment in activities
of daily living.
Secondary outcomes
The study’s secondary outcomes include multimorbidity,
frailty, mobility and functional performance, physical ac-
tivity, psychosocial wellbeing, oral health, nutrition, sleep
quality and health-related quality of life.
Multimorbidity is defined based on medical history
data from e.g. questionnaires, physical assessments, med-
ical records and national registers.
Frailty is defined with the Fried Frailty phenotype
[51], which includes: unintentional weight loss; self-
reported exhaustion; weakness by grip strength; slow
walking speed; and low physical activity. Mobility and
functional performance is assessed based on self-
reported data on mobility and fitness, as well as an
objective and physical assessment, which includes the
Short Physical Performance Battery [43] and the max-
imal isometric handgrip strength measured by a
hand-held adjustable dynamometer.
Physical activity is assessed based on self-reported
questionnaires about frequency and type of activities
carried out.
Assessment of Psychosocial wellbeing cover several do-
mains. Hopelessness, Social network and interactions,
and Subjective memory [59] is investigated through ques-
tionnaires. Anxiety is assessed with the self-reported vali-
dated State Trait Anxiety Inventory [44]. Depressive
symptoms are self-reported through the Beck Depression
Inventory [49]. Significant life events is recorded using a
brief questionnaire based on the Swedish National study
on Aging and Care [60] questionnaire, including major
life events with potential impact on physical, psycho-
logical, and emotional status [61].
Oral health is appraised through a self-report ques-
tionnaire inquiring about oral health status and use of
oral healthcare services. Nutritional status is investigated
using a questionnaire on food consumption frequency,
including alcohol consumption and drinking patterns, as
well as the Mini Nutritional Assessment (short-form)
[52], a validated tool commonly used to screen for and
estimate risk of malnutrition in older adults.
Sleep quality is assessed using the Pittsburgh Sleep
Quality Index [53].
Health-related quality of life is measured with the
RAND 36-Item Health Survey 1.0. [50]
Other data collected
Sociodemographic factors include age, sex, self-reported
data on marital status, living/domicile setting, yearly in-
come, and work history. Other health-related data cover
current medication and medical history; self-reported use
of healthcare services; self-reported type and frequency of
leisure activities; self-reported use of the computer and
the Internet; biometrics such as blood pressure, body mass
index, and waist-hip ratio; smoking habits; information
from medical records, such as diagnoses, hospitalisations,
and other relevant health events. Dates and causes of
death will be obtained from national registers.
Fasting blood samples are collected for assessment of
plasma glucose, glycated haemoglobin (HbA1c); serum
total-, high-density lipoprotein-, and low-density lipo-
protein cholesterol, and triglycerides; c-reactive protein;
and creatinine. Blood samples will also be stored for fu-
ture measurement of other dementia- and aging-related
biomarkers.
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Table 1 Summary of the assessments in the CAIDE study
Data collected and test/scale Midlife-baseline examination
(1972–1992)
1st late-life re-
examination
(1998)
2nd late-life re-
examination
(2005–2009)
3rd re-examination CAIDE85+
(2019–2021)
Socio-demographicsa (e.g. age; sex; self-reported education,
marital status, occupation and income)
X X X X
Lifestylea (questions about e.g. diet, physical exercise, smoking,
leisure activities)
X X X X
Anthropometric measurements (weight, height, BMI, waist
circumference, blood pressure)
X X X X
Blood markersa (e.g. lipids, glucose, CRP, creatinine) X X X X
Medical history (self-reported) X X X X
Medical history (national registers) X X X X
Cognition
CERAD [30] – – X X
MMSE [31] – X Part of
CERAD
Part of CERAD
Immediate word recall (3 word-lists)b [32] – X 1 list –
Category fluency test [33] – X Part of
CERAD
Part of CERAD
Purdue Peg board [34] – X X –
Trail Making Test - part A [35] – – X X
Stroop [36] – X X –
Letter Digit Substitution Test [37] – X X X
Diagnosis of dementia or MCI (3-step protocol [29]) – X X –
Diagnosis of dementia or MCI (national registers) – X X X
Daily life functioning (questions) X X X X
Daily life functioning (ADL: Katz Index and Lawton and Brody
Scale [38–40])
– – – X
Daily life functioning (CDR [41, 42]) – – X X
Physical Functioning (SPPB [43]) – – – X
Stressa (questions) X X X X
Anxiety (6-item STAI [44]) – X X X
Personality-related factors (anger expression [45], cynical
distrust [46], sense of coherence [47], ways of coping [48])
– X – –
Social Network (questions) – X X Shortened
Subjective memorya (questions) – X X X
Hopelessness (questions) X X X X
Depression (BDI [49]) – X X X
Significant life events (questions) – X X Shortened
Health Related Quality of Life (RAND 36 [50]) – – – X
Frailty (Fried phenotype [51]) – – – X
Malnutrition (MNA short version [52]) – – – X
Sleep quality (Pittsburgh Sleep Index [53]) – – – X
Oral health (questions) – – – X
Medication use (self-reported and national registers) – X X X
APOEƐ4 genotyping – X X –
ADL Activity of daily living, APOEƐ4 Apolipoprotein E Ɛ4 allele, BDI Beck depression inventory, BMI body mass index, CDR clinical dementia rating,
CERAD Consortium to Establish a Registry for Alzheimer’s Disease test battery, CRP C-reactive protein, MCI Mild cognitive impairment, MMSE Mini-Mental
State Examination, MNA mini nutritional assessment, SPPB Short physical performance battery, RAND36 RAND 36-Item Health Survey 1.0, STAI State trait
anxiety inventory
a some differences in assessments may exist among different re-examinations
b of the 3 word-lists used in 1998, only one was repeated in 2005–2008
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Ethical considerations
The CAIDE85+ study was approved by the Ethics Com-
mittee, Hospital District of Northern Savo (Finland).
Prior to the study enrolment, written informed consent
is obtained from each participant, as well as their in-
formant, if available. If a participant has received a diag-
nosis of AD or other dementia prior to the time of
enrolment, the ability to autonomously consent to the
study is assessed by the research nurse. If the participant
is deemed unable to provide and informed consent, a le-
gally acceptable representative (LAR), is identified with
the help of the participant, to co-sign the consent form.
Failing to identify a LAR for a participant unable to pro-
vide an informed consent precludes the participation in
the study.
Data analysis
Cross-sectional analyses and descriptive statistics, in-
cluding potential comparisons with other 85+ cohorts
available in the literature will be carried out. Longitu-
dinal analyses combining repeated measures data from
the first two follow-ups, as well as baseline (midlife), will
also be conducted, where applicable. Appropriate statis-
tical methods will be used to analyse the data, including
proportional hazards modelling and appropriate regres-
sion models (e.g. Kaplan-Meier method, logistic, linear,
ordinal, Cox and Poisson regression models). To analyse
different trajectories of predictor variables across mul-
tiple waves of data, path analyses and structural equation
modelling will be used. Mortality will be taken into ac-
count in longitudinal analyses. Novel statistical methods
(e.g. machine learning) [62] may also be tested for multi-
factorial prediction. Statistical significance will be de-
fined at p < 0.05 and relevant guidelines (e.g. STROBE
[63], TRIPOD [64]) will be used for results interpret-
ation and reporting.
Discussion
In the last century, life expectancy has persistently in-
creased to levels earlier often considered unattainable.
Despite recent findings reporting declining life expect-
ancy in the United States and United Kingdom [65, 66],
globally the projections for the next decades confirm this
strong trend [67]. As a consequence, the oldest olds are
now by far the fastest growing age group, in developed
countries in particular [68]. Such shift in the age distri-
bution of the population will affect not only healthcare
systems, but also, more in general, the way in which so-
ciety will cope with ageing-related matters. Living longer
does not necessarily mean living better, as life expect-
ancy and quality of life do not always go hand in hand
[2]. However, evidence suggests that ageing processes
may be modifiable, and people could live longer without
increased disabilities [1].
Dementia, AD, and cognitive impairment constitute,
nonetheless, a major ageing-related social, economic,
and public health concern. With the ageing of popula-
tions, the number of people living with dementia is also
expected to increase rapidly [69]. Additional efforts and
resources are, therefore, needed to improve our under-
standing healthy ageing and its determinants.
The oldest old include individuals often vulnerable to
and impaired by severe disabilities. Thus, extensive in-
vestigation of this age group poses specific ethical and
logistic challenges [70], which can have a great impact
on recruitment success, study implementation, and data
interpretation. Altogether, studies on the oldest old are
scarce and often conducted on relatively small popula-
tion samples. In the last few decades, some large cohort
studies have been conducted focusing on the broad de-
terminants of health in the oldest old [71–75]. How-
ever, in none of them the participants have been
followed-up starting from midlife. Furthermore, recruit-
ment in most of these studies was completed from the
beginning of the 1990s to the early 2000s. In a society
in constant cultural evolution and marked by substan-
tial lifestyle changes linked to increased access to new
technologies, the current nonagenarians are likely to be
a rather different population group than only a few
decades ago.
The CAIDE85+ study represents a rare opportunity to
delve into the determinants of cognitive and physical
health within a current population of oldest old, who
have been followed for decades, since their midlife until
old age. Such a long follow-up time is rarely achievable
in observational studies. A wide range of outcomes from
more specific cognitive measures to medical, physical
and psychological parameters is investigated, using,
whenever possible, methods specifically designed and
particularly relevant for this age group.
Through a thorough investigation of the cognitive and
physical functioning, as well as the incidence of demen-
tia and cognitive impairment, this study will contribute
to improve the knowledge on risk and protective factors
for cognitive impairment and underlying mechanisms,
which may help reduce the detrimental impact of de-
mentia on both individuals and the society. Findings
from this study will also enable us to better understand
the role of lifestyle and medical factors that contribute
to good physical status, successful cognitive ageing, as
well as increased quality of life and healthy ageing in
general at the oldest old ages. It is expected that differ-
ent risk factors would play a key role in different age
groups. This has practical implications in planning pre-
ventive intervention programmes, developing new thera-
peutic strategies, and educating the general population,
as well as healthcare professionals. Therefore, findings
from the study may also help develop interventions
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focused on promotion of healthy ageing, and plan indi-
vidually tailored healthcare for the oldest old age groups.
The high mortality and morbidity rates, as well as the
high prevalence of cognitive impairment expected in a
population of oldest old are potential limitations in this
study, but several provisions have been put in place to
reduce their impact. First, the use of thorough and up-
to-date Finnish health registers will allow us to collect
essential data that could not be obtained otherwise. Sec-
ond, in order to meet the needs of all participants, the
study visits have been designed to have a high degree of
flexibility both in terms of location (research site or par-
ticipant’s domicile) and timing (over one or more ap-
pointments). In particular, the possibility of conducting
home visits and, if needed, in more than one session,
helps reduce the burden and ease the participation also
for individuals who are more disabled. Finally, assessing
cognition using well-validated and widely used tests help
compensate for potential inaccuracies in the collection
of self-reported data.
In conclusion, by providing more detailed insight on
the medical, lifestyle, psychosocial and physical-related
factors contributing to cognitive health; quality of life;
and psychosocial wellbeing among the oldest old, our
findings will produce urgently needed information for
healthcare workers and policy makers to better promote
health and independent living among this rapidly grow-
ing age group.
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